

Infracom - Emerging synergies

Redeye retains its positive view of Infracom following its Q4 2022 report. The sales exceeded our expectations due to substantial acquired growth, while the EBIT margin was somewhat softer than anticipated. Overall, we make minor forecast adjustments that have a slight effect on our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Infracom - Emerging synergies